DESTINY-Lung01 Data Position Trastuzumab Deruxtecan as Next Oncogene-Driven Therapy in NSCLC

Nathan A. Pennell, MD, PhD, discusses the significance of findings from the DESTINY-Lung01 trial in non–small cell lung cancer.

Read the full article here

Related Articles